Compare MNY & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNY | TELA |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.5M | 50.8M |
| IPO Year | N/A | 2019 |
| Metric | MNY | TELA |
|---|---|---|
| Price | $1.25 | $1.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $4.00 | $3.31 |
| AVG Volume (30 Days) | 56.4K | ★ 96.8K |
| Earning Date | 12-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $69,182,746.00 | ★ $77,055,000.00 |
| Revenue This Year | $11.26 | $18.41 |
| Revenue Next Year | $20.70 | $15.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.24 |
| 52 Week Low | $0.55 | $0.86 |
| 52 Week High | $2.40 | $3.08 |
| Indicator | MNY | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 44.63 | 45.69 |
| Support Level | $1.26 | $1.07 |
| Resistance Level | $1.32 | $1.16 |
| Average True Range (ATR) | 0.03 | 0.06 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 0.71 | 34.62 |
MoneyHero Ltd is a personal finance aggregation and comparison company in Greater Southeast Asia. The firm is involved in the operation of online financial comparison platforms and related services for credit cards, personal loans, mortgages, insurance, and other financial products, connecting the providers of these products with well-matched and ready-to-transact consumers and generating revenue directly from these providers for placing their products on its platforms and providing insurance brokerage, marketing and events-related services. Geographically it operates in Singapore, Hong Kong, Taiwan, Malaysia and the Philippines.
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.